Balaxi Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)
Balaxi Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 7:28 pm
Balaxi Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 8,137 (+44.9% YoY | +0.9% QoQ) ■ EBITDA: 512 (+338.0% YoY | +9.8% QoQ) ■ EBITDA Margin (%): 6.3 (+421 bps YoY | +51 bps QoQ) ■ PAT: 115 (+450.3% YoY | -11.3% QoQ) ■ EPS (INR): 0.21 (+425.0% YoY | -12.5% QoQ)
Original exchange filing (PDF)
More announcements from Balaxi Pharmaceuticals Ltd
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation · 16 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding a press release dated November 12, 2026, titled "Balaxi Pharmaceuticals Limited Reports Strong Q2 FY27 Performance; Revenue Grows 45%, EBITDA Surges 338% and PAT Rises 450% YoY". · 13 Nov 2026
- Balaxi Pharmaceuticals Limited has informed the Exchange regarding Progress of the Company's Pharmaceutical Formulation Plant at Jadcherla, Hyderabad. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about change in Management · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on November 12, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended October 2026". · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 12 Nov 2026
- To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters. · 12 Nov 2026
